(Natural News) It has finally been revealed that the participant in AstraZeneca’s Wuhan coronavirus (COVID-19) vaccine trial who suffered a “serious adverse event,” causing a global shutdown of the company’s entire phase-three trial, developed a spinal inflammatory disorder known as transverse myelitis.
Company CEO Pascal Soriot told JP Morgan and other investors over a conference call that the woman from the United Kingdom developed neurological symptoms consistent with this “rare” disease almost immediately following injection, though AstraZeneca insists that the experimental vaccine is not to blame.
The random thoughts of 99th Monkey . . . an occasional rant and other reflections in the hall of mirrors.